The Oncology Institute, Inc.
TOI
$2.71
$0.3213.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.88% | 21.78% | 22.88% | 24.25% | 20.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.88% | 21.78% | 22.88% | 24.25% | 20.11% |
| Cost of Revenue | 19.92% | 29.49% | 31.40% | 33.18% | 27.98% |
| Gross Profit | 1.79% | -10.09% | -13.83% | -15.11% | -8.00% |
| SG&A Expenses | -11.86% | -5.39% | -2.79% | -1.31% | -6.83% |
| Depreciation & Amortization | 8.24% | -7.36% | 14.22% | 17.34% | 32.30% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.88% | 18.59% | 20.86% | 22.18% | 15.96% |
| Operating Income | 22.54% | 0.22% | -9.95% | -12.33% | 2.74% |
| Income Before Tax | 30.87% | 6.78% | 7.85% | 33.60% | -67.65% |
| Income Tax Expenses | -- | -- | -- | -- | 14.44% |
| Earnings from Continuing Operations | 29.71% | 7.50% | 8.39% | 33.70% | -70.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.71% | 7.50% | 8.39% | 33.70% | -70.38% |
| EBIT | 22.54% | 0.22% | -9.95% | -12.33% | 2.74% |
| EBITDA | 26.05% | -0.77% | -9.53% | -11.89% | 5.59% |
| EPS Basic | 31.23% | 9.84% | 9.06% | 34.27% | -73.27% |
| Normalized Basic EPS | 35.34% | 6.15% | 7.19% | -41.26% | -140.47% |
| EPS Diluted | 30.77% | 7.31% | 10.53% | 34.03% | -5.42% |
| Normalized Diluted EPS | 35.34% | 6.15% | 7.19% | -41.26% | -140.47% |
| Average Basic Shares Outstanding | 2.98% | 2.80% | 0.85% | 1.07% | 0.99% |
| Average Diluted Shares Outstanding | 2.98% | 2.80% | 0.85% | 1.07% | 0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |